Literature DB >> 19048065

The use of GEM models for experimental cancer therapeutics.

Aarthi Gopinathan, David A Tuveson.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 19048065      PMCID： PMC2562176          DOI： 10.1242/dmm.000570

Source DB:  PubMed          Journal:  Dis Model Mech        ISSN： 1754-8403            Impact factor:   5.758


× No keyword cloud information.
  19 in total

1.  First clinical trials of endostatin yield lukewarm results.

Authors:  Renee Twombly
Journal:  J Natl Cancer Inst       Date:  2002-10-16       Impact factor: 13.506

2.  A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer.

Authors:  Matthew H Kulke; George D Demetri; Norman E Sharpless; David P Ryan; Ramesh Shivdasani; Jeffrey S Clark; Bruce M Spiegelman; Haesook Kim; Robert J Mayer; Charles S Fuchs
Journal:  Cancer J       Date:  2002 Sep-Oct       Impact factor: 3.360

3.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

Authors:  T Boehm; J Folkman; T Browder; M S O'Reilly
Journal:  Nature       Date:  1997-11-27       Impact factor: 49.962

4.  Direct orthotopic transplantation of fresh surgical specimen preserves CD133+ tumor cells in clinically relevant mouse models of medulloblastoma and glioma.

Authors:  Qin Shu; Kwong Kwok Wong; Jack M Su; Adekunle M Adesina; Li Tian Yu; Yvonne T M Tsang; Barbara C Antalffy; Patricia Baxter; Laszlo Perlaky; Jianhua Yang; Robert C Dauser; Murali Chintagumpala; Susan M Blaney; Ching C Lau; Xiao-Nan Li
Journal:  Stem Cells       Date:  2008-04-10       Impact factor: 6.277

5.  Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse.

Authors:  Sunil R Hingorani; Emanuel F Petricoin; Anirban Maitra; Vinodh Rajapakse; Catrina King; Michael A Jacobetz; Sally Ross; Thomas P Conrads; Timothy D Veenstra; Ben A Hitt; Yoshiya Kawaguchi; Don Johann; Lance A Liotta; Howard C Crawford; Mary E Putt; Tyler Jacks; Christopher V E Wright; Ralph H Hruban; Andrew M Lowy; David A Tuveson
Journal:  Cancer Cell       Date:  2003-12       Impact factor: 31.743

6.  Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.

Authors:  Guido Bocci; Romano Danesi; Gabriele Marangoni; Anna Fioravanti; Ugo Boggi; Irene Esposito; Alessandro Fasciani; Elena Boschi; Daniela Campani; Generoso Bevilacqua; Franco Mosca; Mario Del Tacca
Journal:  Eur J Pharmacol       Date:  2004-09-13       Impact factor: 4.432

Review 7.  Maximizing mouse cancer models.

Authors:  Kristopher K Frese; David A Tuveson
Journal:  Nat Rev Cancer       Date:  2007-09       Impact factor: 60.716

8.  Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer.

Authors:  Sven Rottenberg; Anders O H Nygren; Marina Pajic; Fijs W B van Leeuwen; Ingrid van der Heijden; Koen van de Wetering; Xiaoling Liu; Karin E de Visser; Kenneth G Gilhuijs; Olaf van Tellingen; Jan P Schouten; Jos Jonkers; Piet Borst
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-11       Impact factor: 11.205

Review 9.  The three Es of cancer immunoediting.

Authors:  Gavin P Dunn; Lloyd J Old; Robert D Schreiber
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

10.  A mouse to human search for plasma proteome changes associated with pancreatic tumor development.

Authors:  Vitor M Faca; Kenneth S Song; Hong Wang; Qing Zhang; Alexei L Krasnoselsky; Lisa F Newcomb; Ruben R Plentz; Sushma Gurumurthy; Mark S Redston; Sharon J Pitteri; Sandra R Pereira-Faca; Renee C Ireton; Hiroyuki Katayama; Veronika Glukhova; Douglas Phanstiel; Dean E Brenner; Michelle A Anderson; David Misek; Nathalie Scholler; Nicole D Urban; Matt J Barnett; Cim Edelstein; Gary E Goodman; Mark D Thornquist; Martin W McIntosh; Ronald A DePinho; Nabeel Bardeesy; Samir M Hanash
Journal:  PLoS Med       Date:  2008-06-10       Impact factor: 11.069
View more
  18 in total

Review 1.  Nanomedicinal strategies to treat multidrug-resistant tumors: current progress.

Authors:  Xiaowei Dong; Russell J Mumper
Journal:  Nanomedicine (Lond)       Date:  2010-06       Impact factor: 5.307

2.  Manipulating the Mouse Genome Using Recombineering.

Authors:  Kajal Biswas; Shyam K Sharan
Journal:  Adv Genet Eng       Date:  2013-06-27

3.  DNA methyltransferase inhibitor, zebularine, delays tumor growth and induces apoptosis in a genetically engineered mouse model of breast cancer.

Authors:  Min Chen; Daniel Shabashvili; Akbar Nawab; Sherry X Yang; Lisa M Dyer; Kevin D Brown; Melinda Hollingshead; Kent W Hunter; Frederic J Kaye; Steven N Hochwald; Victor E Marquez; Patricia Steeg; Maria Zajac-Kaye
Journal:  Mol Cancer Ther       Date:  2011-12-27       Impact factor: 6.261

4.  CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer.

Authors:  Albrecht Neesse; Kristopher K Frese; Tashinga E Bapiro; Tomoaki Nakagawa; Mark D Sternlicht; Todd W Seeley; Christian Pilarsky; Duncan I Jodrell; Suzanne M Spong; David A Tuveson
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-08       Impact factor: 11.205

Review 5.  The pancreas cancer microenvironment.

Authors:  Christine Feig; Aarthi Gopinathan; Albrecht Neesse; Derek S Chan; Natalie Cook; David A Tuveson
Journal:  Clin Cancer Res       Date:  2012-08-15       Impact factor: 12.531

Review 6.  Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents.

Authors:  Sreenath V Sharma; Daniel A Haber; Jeff Settleman
Journal:  Nat Rev Cancer       Date:  2010-03-19       Impact factor: 60.716

Review 7.  Chemoprevention of pancreatic cancer-one step closer.

Authors:  Volker Fendrich
Journal:  Langenbecks Arch Surg       Date:  2012-02-15       Impact factor: 3.445

Review 8.  Choosing The Right Animal Model for Renal Cancer Research.

Authors:  Paweł Sobczuk; Anna Brodziak; Mohammed Imran Khan; Stuti Chhabra; Michał Fiedorowicz; Marlena Wełniak-Kamińska; Kamil Synoradzki; Ewa Bartnik; Agnieszka Cudnoch-Jędrzejewska; Anna M Czarnecka
Journal:  Transl Oncol       Date:  2020-02-22       Impact factor: 4.243

9.  Kinetics of angiogenic changes in a new mouse model for hepatocellular carcinoma.

Authors:  Femke Heindryckx; Koen Mertens; Nicolas Charette; Bert Vandeghinste; Christophe Casteleyn; Christophe Van Steenkiste; Dominique Slaets; Louis Libbrecht; Steven Staelens; Peter Starkel; Anja Geerts; Isabelle Colle; Hans Van Vlierberghe
Journal:  Mol Cancer       Date:  2010-08-20       Impact factor: 27.401

10.  Intracaecal Orthotopic Colorectal Cancer Xenograft Mouse Model.

Authors:  Hsin-Wei Liao; Mien-Chie Hung
Journal:  Bio Protoc       Date:  2017-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.